Literature DB >> 32151609

Design of human lactoferricin derived antitumor peptides-activity and specificity against malignant melanoma in 2D and 3D model studies.

Sarah Grissenberger1, Sabrina Riedl2, Beate Rinner3, Regina Leber4, Dagmar Zweytick5.   

Abstract

The aim of this study was to develop effective and specific anti-cancer drugs based on membrane active peptides. In previous studies we showed that human lactoferricin (hLFcin) derived peptides facilitate specific killing of cancer cells. These antitumor peptides were found by conventional melanoma two-dimensional (2D) cell cultures to induce apoptosis of cancer cells and to specifically target lipid phosphatidylserine located on the outside of cancer cell membranes. In order to have a more relevant in vitro model able to mimic the natural microenvironments of tumor tissues we established three-dimensional (3D) multicellular tumor spheroids (MCTS). We used a set of (retro) di-peptides derived from LF11, an 11 amino acid long fragment of hLFcin, which differed in peptide length, positive net charge and hydrophobicity and determined antitumor activity and non-specific toxicity on non-neoplastic cells using 2D and 3D model systems. 2D studies unveiled a correlation between length, positive net charge and hydrophobicity of peptides and their specific antitumor activity. (Retro) di-peptides as R-DIM-P-LF11-215 and DIM-LF11-322 with a net charge of +9 and moderate hydrophobicity exhibited the highest specific antitumor activity. Further evaluation of the peptides anticancer activity by 3D in vitro studies confirmed their higher activity and cancer specificity compared to their parent R-DIM-P-LF11, with the exception of DIM-LF11-339. This highly hydrophobic peptide caused cell death mainly at the border of tumor spheroids indicating that too high hydrophobicity may prevent peptides from reaching the center of the spheroids.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  2D and 3D in vitro studies; Antitumor peptides; Lactoferricin; Melanoma

Year:  2020        PMID: 32151609     DOI: 10.1016/j.bbamem.2020.183264

Source DB:  PubMed          Journal:  Biochim Biophys Acta Biomembr        ISSN: 0005-2736            Impact factor:   3.747


  3 in total

Review 1.  The Challenging Melanoma Landscape: From Early Drug Discovery to Clinical Approval.

Authors:  Mariana Matias; Jacinta O Pinho; Maria João Penetra; Gonçalo Campos; Catarina Pinto Reis; Maria Manuela Gaspar
Journal:  Cells       Date:  2021-11-09       Impact factor: 6.600

Review 2.  Peptides with Dual Antimicrobial-Anticancer Activity: Strategies to Overcome Peptide Limitations and Rational Design of Anticancer Peptides.

Authors:  Yamil Liscano; Jose Oñate-Garzón; Jean Paul Delgado
Journal:  Molecules       Date:  2020-09-16       Impact factor: 4.411

3.  MUG Mel3 Cell Lines Reflect Heterogeneity in Melanoma and Represent a Robust Model for Melanoma in Pregnancy.

Authors:  Silke Schrom; Thomas Hebesberger; Stefanie Angela Wallner; Ines Anders; Erika Richtig; Waltraud Brandl; Birgit Hirschmugl; Mariangela Garofalo; Claudia Bernecker; Peter Schlenke; Karl Kashofer; Christian Wadsack; Ariane Aigelsreiter; Ellen Heitzer; Sabrina Riedl; Dagmar Zweytick; Nadine Kretschmer; Georg Richtig; Beate Rinner
Journal:  Int J Mol Sci       Date:  2021-10-20       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.